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Abstract
MNT, a transcription factor of the MXD family, is an important modulator of the oncoprotein MYC. Both MNT and MYC
are basic-helix–loop–helix proteins that heterodimerize with MAX in a mutually exclusive manner, and bind to E-boxes
within regulatory regions of their target genes. While MYC generally activates transcription, MNT represses it. However,
the molecular interactions involving MNT as a transcriptional regulator beyond the binding to MAX remain
unexplored. Here we demonstrate a novel MAX-independent protein interaction between MNT and REL, the
oncogenic member of the NF-κB family. REL participates in important biological processes and it is altered in a variety
of tumors. REL is a transcription factor that remains inactive in the cytoplasm in an inhibitory complex with IκB and
translocates to the nucleus when the NF-κB pathway is activated. In the present manuscript, we show that MNT
knockdown triggers REL translocation into the nucleus and thus the activation of the NF-κB pathway. Meanwhile, MNT
overexpression results in the repression of IκBα, a bona fide REL target. Both MNT and REL bind to the IκBα gene on
the first exon, suggesting its regulation as an MNT–REL complex. Altogether our data indicate that MNT acts as a
repressor of the NF-κB pathway by two mechanisms: (1) retention of REL in the cytoplasm by MNT interaction, and (2)
MNT-driven repression of REL-target genes through an MNT–REL complex. These results widen our knowledge about
MNT biological roles and reveal a novel connection between the MYC/MXD and NF-κB pathways, two of the most
prominent pathways in cancer.
Introduction
MNT is a protein from the MYC/MAX/MXD/MLX
network of transcription factors, which has a pivotal role
in controlling cell proliferation, differentiation, metabo-
lism, and oncogenic transformation. MNT is a basic-
helix–loop–helix leucine zipper (bHLHLZ) protein that
regulates transcription as heterodimers with MAX1,2 or
MLX3 but also as homodimers4. Hence MNT connects the
MYC-MAX and MLX-Mondo branches of the network5.
MNT normally represses gene transcription by binding to
E-boxes and interacting with SIN3 proteins that, in turn,
recruit histone deacetylase complexes to its target genes1,6.
Among the MXD proteins, MNT is the biggest as well
as the most ubiquitously expressed and conserved mem-
ber7,8. Whereas Mxd1−/−, Mxi1−/−, and Mxd3−/− mice
survive, mice knockout for Mnt die soon after birth9–12.
Thus, MNT is a unique and essential protein of this
network. MNT is also frequently deleted in cancer, e.g., in
chronic lymphocytic leukemia, Sézary syndrome (a var-
iant of cutaneous T-cell lymphoma), and medullo-
blastoma13–16. Indeed, around 10% of the tumors show
deletions of an MNT allele17.
MNT has an important role in modulating the onco-
genic activities of MYC whether as an antagonist and
tumor suppressor or as a cooperator7. MNT-MYC
antagonism is achieved at three different levels: (i)
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competition for binding to MAX; (ii) competition
between MNT–MAX and MYC-MAX for binding to the
E-Boxes of their shared target genes; (iii) transcriptional
repression of shared target genes that are normally acti-
vated by MYC-MAX9,10. This antagonism can explain
why the deletion of MNT leads to tumor formation in
mouse mammary epithelium and T-cells9,10. However,
other studies suggest that MYC needs the pro-survival
functions of MNT for fully achieving its transformation
potential. This is the case of MYC-driven B- and T-cell
lymphoma models, where MNT deficiency impairs MYC-
driven tumorigenesis9,10,18.
Nevertheless, there are several unsolved questions about
the MNT mechanism of action. All the functions descri-
bed so far for MNT have been attributed to MNT–MAX
dimers. However, MAX is deleted in some cancers, as
pheochromocytoma, paraganglioma, gastrointestinal
stromal tumors, and small cell lung cancer19–21. More-
over, we have recently described MAX-independent MNT
activities in cell proliferation and gene transcription4.
Thus, we hypothesized that there are MNT functions
dependent on the interaction with other proteins different
from MAX. In this work, we have investigated new MNT
interactions in a MAX-independent setting and identified
c-REL (REL hereafter), a member of the NF-κB’s family, as
an MNT interacting protein. NF-κB signaling pathway has
a major role in proliferation, differentiation, and apopto-
sis, particularly in cells from the immune system22,23. REL
was first described by homology with v-rel, the oncogene
from the avian reticuloendotheliosis virus24. Importantly,
REL is the only NF-κB protein with transforming ability25
and is altered in a variety of tumors26. In the present
manuscript, we show that MNT deletion leads to (1)
translocation of REL into the nucleus and activation of the
NF-κB pathway, and (2) REL-dependent inhibition of cell
proliferation. This suggests that MNT maintains cell
survival through the regulation of the NF-κB pathway.
Moreover, MNT–REL complexes bind to an NF-κB target
gene, NFKBIA/IκBα, a protein required to retain NF-κB
dimers in the cytoplasm in the absence of activating sti-
mulus23. In summary, this work describes the first evi-
dence of physical interaction between the MYC-MAX-
MNT and NF-κB pathways and provides an insight into
the relevance of MNT in cell biology.
Results
Searching for new MNT partners
To find proteins that interact with MNT in a MAX-
independent way, we performed proteomic analysis of
MNT immunoprecipitates in UR61-derived cells, which
come from a rat pheochromocytoma and lack a functional
MAX gene27. We used URMax34, a cell line with a
Zn2+-inducible MAX allele and its control cells (URMT),
which were transfected with the empty vector4. MNT was
immunoprecipitated by triplicate for each cell line and
subjected to mass spectrometry. The results showed 11
proteins that were reproducibly immunoprecipitated in
URMT and 47 in URMax34 (Supplementary Table 1).
Five proteins were shared between the two cell lines: REL,
CCDC6, AMPD2, QSER1, and TPP2 (Fig. 1a). Given the
Fig. 1 Proteins interacting with MNT. a Top: Schematic representation of the proteomic study: URMT and URMax34 cells were treated with 100 µM
Zn2SO4 for 24 h and lysed for posterior MNT immunoprecipitation. Six independent immunoprecipitations were analyzed by mass
spectrophotometry and five proteins were found bound to MNT in URMT and URMax34. Bottom: Quantification of the protein interactions. The bar
graphs represent mean LFQ intensity values of the selected MNT interactions ± S.D. (n= 6). P < 0.05 with respect to IgG. b Immunoblot of MNT and
REL in different cell lines: URMT (control UR61) and URMax34 (UR61 with MAX expression induced by Zn2+); C6 (rat brain glioma); Neuro-2a (mouse
neuroblastoma); Lu165 (small cell lung cancer); NP9 (human pancreatic adenocarcinoma); LoVo and HT-29 (human colorectal adenocarcinoma);
HaCaT (human keratinocyte). β-actin levels were determined as a protein loading control.
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relevance of the NF-κB pathway in cell biology, we
selected REL for further studies. First, we tested the
protein expression of MNT and REL levels in several cell
lines, including URMT and URMax34 cells, by western
blot (Fig. 1b). As we recently described, MNT expression
was higher in the URMT cells lacking MAX4.
Next, we confirmed MNT–REL interaction by co-
immunoprecipitation (co-IP) assays followed by western
blot. REL was present in MNT immunoprecipitates of
URMax34 cells induced to express MAX. In this model,
we confirmed the MNT–MAX co-IP. However, REL was
not present in the MAX immunoprecipitates, indicating
that there was no interaction of REL with MAX (Fig. 2a).
We also found REL-MNT co-IP in mouse Neuro-2a (Fig.
2b), human colon cancer LoVo (Fig. 2c), and rat glioma
C6 cells (Fig. 2d, left). MNT–REL interaction was not
detected in other cell lines tested, e.g., SH-SY5Y (neuro-
blastoma), HEK293T (embryonic kidney), K562 (chronic
myeloid leukemia), A549 and H1299 (lung cancer), and
HEPG2 (hepatocellular carcinoma).
We also detected MNT–REL interaction in immuno-
precipitates with anti-REL antibodies in LoVo cells (Fig.
2c), C6 (Fig. 2d), and URMT cells (not shown). Next, we
wanted to confirm the interaction between MNT and REL
through proximity ligation assays. We transfected C6 cells
with MNT and REL expression vectors and obtained a
positive result of MNT–REL interaction (Fig. 2e). The
interaction was also observed in untransfected LoVo cells,
although the signal was less intense (Fig. 2f). The inter-
actions between MYC-MAX and p65-REL were used as
positive controls of the assay. MYC-REL and MNT-MYC
were used as negative controls.
REL is generally found forming homodimers or het-
erodimers with p65 or p5022. To assess whether there was
any p65 or p50 in the MNT–REL complex, we immu-
noprecipitated p65 to show the p65-REL interaction in
UR61 cells with and without MAX. We observed p65-REL
interaction but not the p65-MNT co-IP (Fig. 3a). We also
performed co-IP assays using two different antibodies
against MNT, recognizing the first 1–50 amino acids and
the amino acids 532–582, respectively. In addition, we
used antibodies anti-p65 and p105/p50. The results
showed that, in LoVo cells, REL co-immunoprecipitated
with the anti-MNT antibody recognizing the MNT 1–50
amino acids but not in the anti-MNT recognizing the
amino acids 532–582 (Fig. 3b). The binding of the anti-
body to the 532–582 amino acids of MNT may disrupt
MNT–REL co-IP, which suggests the implication of MNT
C-terminal domain in the interaction. MAX co-IP was
detected in both MNT immunoprecipitates (positive
control) (Fig. 3b). However, neither p65 nor p50 was
found to interact with MNT in any of the IPs. REL co-
immunoprecipitated with p65 and p50 as expected. Since
p65 and p50 did not interact with MNT, it is possible that
the MNT–REL complex may be composed of REL
homodimers or REL bound to other unknown protein(s),
as schematically represented in Fig. 3c.
To determine the domain of MNT involved in the
interaction with REL, we used two MNT deletion mutants
tagged with the HA epitope: ΔbHLH (lacking the bHLH
domain, residues 221–272) and ΔCt1 MNT-HA (lacking
the C-terminal region of 276 residues) (Fig. 3d). We
transfected these constructs along with a construct
expressing wild-type mouse REL into C6 cells. Interest-
ingly, REL appeared bound to ΔbHLH but not to ΔCt1
(Fig. 3e). We repeated this same procedure with two
MNT N-terminal deletion constructs, ΔNt1 (lacking
residues 1–300) and ΔNt2 MNT-HA (lacking 1–271
residues) (Supplementary Fig. S1a). Both ΔNt1 MNT-HA
and ΔNt2 MNT-HA interacted with REL (Supplementary
Fig. S1b). Altogether, these data show that the C-terminal
region of MNT is necessary for the formation of
MNT–REL complexes, but not its bHLHLZ domain. We
also assayed a REL mutant lacking the REL Inhibitory
Domain (RID), which is a transactivation inhibitory
domain not involved in IκB binding22,28 (Supplementary
Fig. S1c). The co-IP experiments showed that the deletion
of RID abrogated the interaction with MNT (Supple-
mentary Fig. S1d). Thus, the interaction takes place
between the MNT C-terminal region and the RID region
of REL (Fig. 3d).
Next, we investigated the localization of MNT–REL
complexes carrying out a nucleus-cytoplasm fractionation
in C6 cells. The co-IP was performed in basal conditions
and after 30 min of stimulation with TNFα (which pro-
motes the translocation of REL to the nucleus)29. The
results showed that the MNT–REL complex localizes in
the cytoplasm in normal conditions but also in the
nucleus upon activation of the NF-κB pathway by TNFα
(Fig. 3f).
MNT acts as a repressor of the NF-κB’s pathway
We asked whether this novel MNT–REL interaction
had any impact on the NF-κB signaling. As NF-κB dimers
translocate to the nucleus upon the activation of the
pathway, we knocked down MNT in LoVo cells and
performed immunofluorescence assays for REL and p65
to assess their cellular localization. Strikingly, REL accu-
mulated inside the nucleus after MNT knockdown, sug-
gesting an activation of the pathway. On the contrary, p65
remained in the cytoplasm regardless of MNT levels (Fig.
4a). This was confirmed by densitometry of the REL and
p65 immunofluorescence signals (Supplementary Fig. S2).
We next asked whether MNT knockdown would cause
the release of REL from IĸBα by co-IP assays in LoVo
cells. The results showed that despite IĸBα levels were
increased upon MNT silencing, IĸBα-REL complexes
decreased when compared to the control (shScrambled)
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Fig. 2 MNT and REL physically interact. a Co-immunoprecipitation assay with anti-MNT and anti-MAX antibodies in URMax34 cells after Zn2+
treatment. MAX was used as a positive control for MNT immunoprecipitations. The asterisk marks the position of the heavy IgG band. b Co-
immunoprecipitation assay with anti-MNT in mouse Neuro-2a cells. c Co-immunoprecipitation assay in human LoVo cells with anti-MNT and anti-REL.
Two immunoblot images of the blots with high and low intensity are shown. Note that the hypotonic buffer required for MNT–REL co-
immunoprecipitation does not extract efficiently MNT protein. d Co-immunoprecipitation assay in rat glioma C6 cells with anti-MNT and anti-REL
antibodies. The asterisk marks the position of the light IgG band. e rpoximity ligation assay (PLA) performed in C6 cells 48 h after transfection with WT
MNT-HA and REL-flag overexpressing vectors. Antibodies anti-MNT/anti-REL, anti-MYC/anti-MAX (positive control), and anti-MYC/anti-REL (negative
control). The PLA-positive signal in red and DAPI as a nuclear marker. f PLA in LoVo cells (untransfected cells) with anti-MNT/anti-REL, anti-p65/anti-
REL (positive control), and anti-MNT/anti-MYC (negative control) antibodies. The PLA-positive signal is in red and DAPI staining was used as a nuclear
marker.
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Fig. 3 (See legend on next page.)
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(Fig. 4b, left). This was confirmed by densitometry (Fig.
4b, right). We also analyzed the protein levels of MNT
and NF-ĸB proteins after MNT knockdown. The results
showed an increase in p65 and a decrease of REL and p50
protein levels when MNT levels were reduced (Fig. 4c).
Since REL was being translocated to the nucleus upon
MNT knockdown, we monitored the activation of the NF-
ĸB pathway by luciferase assays with a synthetic construct
carrying 5 κB binding sites (pNF-ĸB-Luc). This is a well-
established method to measure NF-κB transcriptional
activity30. The luciferase activity significantly increased
upon MNT knockdown both in LoVo and UR61 cells (Fig.
4d). Our previous work showed that MNT can act not
only as MNT–MAX dimers but also as MNT homo-
dimers4. To study whether MNT acts in concert with
MAX to repress IĸBα promoter, we tested the luciferase
activity of the pNF-ĸB-Luc reporter in URMax34 cells, a
UR61 derivative in which MAX can be induced by Zn2+ 4.
In this model, MNT knockdown showed a similar eleva-
tion of promoter activity in the absence or presence of
MAX (Fig. 4d). MNT knockdown and MAX induction
were confirmed by immunoblot (Supplementary Fig. S3a).
Depletion of MNT results in decreased UR61 cell pro-
liferation cells as described4 and in LoVo cells (Fig. 4e). In
view of the MNT–REL interaction, we asked whether this
effect of MNT was dependent on REL. Conversely to the
depletion of MNT, depletion of REL in UR61 and LoVo
cells did not result in a significant decrease in cell pro-
liferation. However, the concomitant depletion of REL
rescued the proliferation inhibition by MNT (Fig. 4e).
These results suggest that the inhibition of proliferation
upon MNT knockdown is mediated by REL. We con-
firmed MNT and REL knockdowns by immunoblot
(Supplementary Fig. S3b).
MNT directly regulates NFKBIA/IκBα
We tested the expression of four NF-ĸB target genes
(BCL-XL/BCL2L1, CCL5, IL6, IL8) upon MNT knock-
down (Fig. 5a, upper panel) and MNT overexpression
(Fig. 4e, lower panel). The results confirmed the repressor
effect of MNT on the NF-ĸB pathway.
Given the effects of MNT on the levels of proteins of the
NF-κB pathway (Fig. 4c), we asked whether this effect was
exerted at the transcriptional level. LoVo cells were
transfected with an MNT expression vector to analyze the
mRNA levels. The results showed repression of RELA and
NFKBIA after MNT overexpression while REL and
NFKB1 expression did not change (Fig. 5b). We focused
on NFKBIA (IκBα), a repressor of the pathway that is
induced by REL22,31. To confirm the regulation of
NFKBIA/IκBα by MNT, we compared NFKBIA mRNA
levels after overexpressing either wild-type, ΔbHLH (no
binding to DNA) or ΔCt1 MNT (unable to interact with
REL). The results showed that the repression of NFKBIA
was not detected with either of the deletion mutants (Fig.
5c). The results suggested a possible regulation of
NFKBIA by an MNT–REL complex at the transcriptional
level. Thus, we studied whether MNT was able to repress
IκBα through reporter-luciferase assays. Using a construct
carrying the promoter of NFKBIA (IĸBα-Luc), we found
that increased MNT levels led to a repression of NFKBIA
promoter activity. Consistently with this result, the
depletion of MNT through shMNT constructs led to the
activation of the NFKBIA promoter (Fig. 5d).
To test whether MNT was bound to the IκBα promoter,
we analyzed the ChIP-seq data from the ENCODE con-
sortium in the K562 cell line. We observed two coincident
peaks of MNT, MYC, and MAX on the NFKBIA gene,
suggesting bona fide binding sites for dimers of the MYC-
MAX-MNT protein family. The transcriptional repressor
and MNT partner SIN3A also bound NFKBIA/IκBα (Fig.
6a). MNT and REL ChIP experiments were performed in
LoVo cells, which show constitutive NF-κB activation32.
We analyzed regions of the NFKBIA gene −1000 bp to
+1000 bp from the TSS, which include some conserved
REL-binding sites (Fig. 6b). The results showed MNT and
REL binding to the NFKBIA gene (Fig. 6c). Interestingly,
both MNT and REL had a maximum binding at +171/
+343 bp, in the first exon of NFKBIA. To analyze whether
both MNT and REL were bound as a complex, we carried
out a re-ChIP experiment. For this, we first immunopre-
cipitated chromatin with anti-MNT, and then, MNT-
(see figure on previous page)
Fig. 3 MNT interacts with REL through its C-terminal region in the cytoplasm and the nucleus. a Co-immunoprecipitation assays with anti-
MNT and anti-p65 antibodies (the IgG as a negative control) in URMT and URMax34 after Zn2+ treatment. The inputs are shown in the left panel. b
Co-immunoprecipitation assay with MNT antibodies (MNT50, an antibody against the 50 first amino acids of MNT protein; MNT582, an antibody
against the 532–582 amino acids of MNT protein), and with p65 and p105/p50 antibodies, and IgG as a negative control. Two immunoblots for REL
are shown (low and high intensity). c Working hypothesis with two options: MNT bound to REL homodimers, MNT bound to REL and other yet
unknown protein(s). d Schematic representation of the mouse MNT deletion constructs used for the co-IP assays, ΔbHLH and ΔCt1 MNT-HA. The
dotted red lines connect the domains of MNT and REL necessary for the interaction. e C6 cell lysates 48 h after transfection with REL-flag (mouse) and
ΔbHLH or ΔCt1 MNT-HA (mouse) were immunoprecipitated with anti-HA antibodies (IgG as negative control). The immunoblot of HA and REL is
shown. The asterisk marks the heavy IgG band. f C6 cells were lysed following the nucleus/cytoplasm fractionation protocol, both in basal conditions
or 30 min after treatment with TNFα (100 ng/mL) and immunoprecipitated with an anti-MNT antibody or the IgG (the latter as a negative control).
The presence of REL, MNT, and MAX was determined in the immunoprecipitates by immunoblot. RhoGDI and SIN3B were analyzed as cytoplasm and
nucleus markers, respectively. Coomassie blue was used as a protein loading control for the inputs. The asterisk marks the light IgG band.
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Fig. 4 MNT acts as a repressor of the NF-κB’s pathway. a Immunofluorescence of REL (left panel) or p65 (right panel) in LoVo cells that were
infected with lentiviral particles carrying two shRNAs against MNT (shMNT) or a scrambled shRNA (shSCR), and selected with puromycin (1 µg/mL) for
72 h. DAPI as a nuclear marker. b LoVo cell lysates 72 h after infection with shRNAs against MNT (shMNT) or a scrambled shRNA (shSCR), as control
were immunoprecipitated with anti-REL antibodies (IgG as negative control). The immunoblots of REL and IκBα in the inputs and the IPs are shown.
Right graph: the protein levels of the IκBα co-IP versus the REL IP in both conditions were quantified. The data are shown as the mean ± S.D., n= 2,
**P < 0.05. c Protein levels of MNT, REL, p65, p105/p50 in LoVo cells 72 h after infection with lentiviral particles carrying two shRNAs against MNT or a
scrambled shRNA (shSCR), as a control. β-Actin used as a protein loading control. d Top: Schematic representation of the luciferase reporter driven by
five NF-κB binding sites used in these experiments (pNF-kB-Luc). Bottom: NF-κB-mediated promoter activity. LoVo cells were infected with lentiviral
particles carrying two shRNAs against MNT (or a scrambled shRNA as a control, shSCR). Then, 48 h after the infection, cells were selected with
puromycin (1 µg/mL) for 72 h and then transfected with the luciferase reporter. Cells were harvested 48 h after the transfection with the luciferase
constructs and the luciferase activity determined. UR61 and URMax34 cells were transfected with the shRNAs and luciferase constructs and harvested
72 h after the transfection for the luciferase assay (URMax34 cells untreated and treated with 100 µM ZnSO4 for 24 h). Results are expressed in relative
luciferase units (R.L.U.) after normalizing each condition first to the empty luciferase reporter (ELR) and then to the shSCR vector. The data are shown
as the mean ± S.D., n= 3 (LoVo), n= 4 (UR61 and URMax34). **P < 0.05, ***P < 0.01. e REL is required for MNT function in maintaining cell
proliferation. UR61 and LoVo cells were infected with lentivirus expressing short-hairpin (sh) RNA sequences for silencing MNT and REL as indicated.
Seven days after infection the cells on the plates were stained with crystal violet and the color was quantified ± S.D. The data were normalized to the
proliferation of cell infected with the lentiviral empty vector (EV), n= 4 (LoVo) or n= 3 (UR61)), *P < 0.1, **P < 0.05; ***P < 0.01. Images of the LoVo
stained plates on day 7 of a representative experiment is shown below.
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Fig. 5 (See legend on next page.)
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bound chromatin was immunoprecipitated with anti-REL
antibodies. The results showed binding of MNT–REL to
the +171/+343 region. As a positive control, REL→ p50
re-ChIP gave a positive signal on −67/−316, a predicted
REL-binding site in that region (Fig. 6d).
Altogether, the data suggest that MNT inhibits the NF-
κB pathway by retaining REL dimers in the cytoplasm and
by repressing genes normally activated by REL in the
nucleus. When MNT levels drop, the NF-κB pathway is
activated, as REL dimers are released and they induce the
transcription of several NF-κB target genes (Fig. 6e).
Discussion
Here we report evidence of the involvement of MNT in
the regulation of one of the most important signaling
pathways: the NF-κB pathway. First, MNT and REL
interact in some mouse, rat, and human cell lines, and this
complex can be found in both cytoplasm and nucleus.
Second, MNT knockdown triggers REL (but not p65)
translocation into the nucleus and the NF-κB pathway
activation. MNT knockdown also impairs cell prolifera-
tion in a REL-dependent manner. Third, MNT–REL
complex binds to and regulates a crucial NF-κB target
gene: NFKBIA/IκBα. Interestingly, MNT and REL inter-
action is independent of MAX, as it also takes place in
MAX-deficient cells and REL was not found in MAX
immunoprecipitates. The fact that we did not detect
MNT–REL interaction in all the cell lines tested indicates
that the interaction may depend on another ancillary
protein which expression may vary among cell types. This
would affect the efficiency of the co-immunoprecipitation
and the proximity ligation assays, leading to a more dif-
ficult detection of MNT and REL interaction. Although
REL forms heterodimers with p65 or p5022, we did not
detect any of them bound to MNT, which suggests that
MNT binds specifically to REL. The C-terminal region of
MNT, which is rich in prolines, was necessary for the
interaction with REL2. These proline-rich regions are
usually involved in protein–protein interactions33. This
agrees with the result showing that REL is found in MNT
immunoprecipitates when using an antibody recognizing
the first 50 amino acids of MNT but not when using an
antibody recognizing the C-terminal domain of MNT.
This result can be explained because the binding of the
antibody against the MNT C-terminal domain may dis-
rupt the MNT–REL interaction. We also demonstrated
that REL Inhibitory Domain (RID) is needed for the for-
mation of MNT–REL complexes. In addition, we showed
that the MNT–REL complex is found in the cytoplasm
under basal conditions but also in the nucleus after TNFα
stimulation, suggesting a transcriptional function of the
complex.
MNT knockdown provoked the dissociation of the REL-
IκBα complexes and the translocation of REL to the
nucleus, commonly observed when the NF-κB pathway is
activated34. In fact, we demonstrate the activation of the
NF-κB pathway upon MNT silencing, as assessed by a
luciferase NF-κB responsive reporter and the increased
expression of several NF-κB target genes. In accordance
with this result, some NF-κB target genes were down-
regulated after MNT overexpression. Thus, MNT might
be acting as a limiter of NF-κB activity in the absence of
specific activators of the pathway. We also show that
MNT regulates the NF-κB pathway independently of
MAX. We have previously published MAX-independent
functions of MNT4. This novel MNT function supports
our idea that MNT has functions beyond its partner
MAX, not explored before.
NFKBIA encodes IκBα, which binds to and retains the
NF-κB members in the cytoplasm under the absence of
stimulatory signals34. Once a stimulus is detected by the
cell, the NF-κB pathway is activated and IκBα degraded.
However, NF-κB also induces a negative feedback loop,
leading to the transcription of NFKBIA/IκBα. The newly
synthesized IκBα enters the nucleus and shuttles NF-κB
dimers back to the cytoplasm to terminate transcrip-
tion35–37. Thus, IκBα levels analysis is a reliable method to
study the transcriptional activity of NF-κB38. ChIP assays
(see figure on previous page)
Fig. 5 MNT directly regulates NFKBIA (IκBα). a mRNA levels of MNT, REL, CCL5, IL6, IL8, BCL2L1 (BCL-XL) in LoVo cells 72 h after infection with
shRNAs against MNT (shMNT) or a scrambled shRNA (shSCR) (upper panel) or 48 h after transfection with an MNT overexpressing construct or it’s
corresponding empty vector (EV) (lower panel) relative to RPS14 expression. The data are shown as the mean ± S.D., n ≥ 3, *P < 0.1, **P < 0.05; ***P <
0.01. b mRNA levels of MNT, REL, RELA, NFKB1, NFKBIA in LoVo cells 48 h after transfection with an MNT overexpressing construct or it’s corresponding
empty vector (EV) relative to RPS14 expression. The data are shown as the mean ± S.D., n= 4, **P < 0.05; ***P < 0.01. c mRNA levels of NFKBIA in LoVo
cells 48 h after transfection with a WT MNT, ΔbHLH, or ΔCt1 MNT-HA overexpressing construct, or their corresponding empty vector (EV) relative to
RPS14 expression. The data are shown as the mean ± S.D., n= 6 (WT), n= 3 (mutants) ***P < 0.01. d Top: Schematic representation of the luciferase
reporter driven by the human NFKBIA (IĸBα) promoter (IĸBα-Luc) used in this work. For the luciferase assay overexpressing MNT, the luciferase activity
was measured 48 h after transfection with the luciferase vectors and MNT expression vector or their corresponding empty vectors (on the left). For
the luciferase assay after MNT knockdown, cells were first infected with lentiviral particles carrying two shRNAs against MNT (or a scrambled shRNA as
a control, shSCR), selected with puromycin (1 µg/mL) for 72 h and then transfected with the luciferase vectors (on the right). Results are expressed in
relative luciferase units (R.L.U.) after normalizing each condition first to the luciferase empty reporter (ELR) and then to the empty vector of MNT
(pCMVSport6) (left) or the shSCR (right). The data are shown as the mean ± S.D., n= 3 (shMNT), n= 4 (MNT), ***P < 0.01.
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show the binding of MNT and REL to the first exon of the
IκBα gene and re-ChIP experiments confirm that MNT
and REL bind together to that same region. MNT and
other MXD proteins exert a transcriptional repressive
effect in many genes due to the interaction with SIN3 co-
repressor1,39. The ENCODE data shows SIN3A binding to
the NFKBIA/IκBα gene, which can explain the tran-
scriptional repression of the gene. The fact that MNT can
Fig. 6 MNT and REL regulate NFKBIA. a Schematic representation of human NFKBIA (IκBα) gene showing the peaks for MNT, MYC, MAX (K562 cell
line), and SIN3A (GM78), as published by the ENCODE project consortium (genome-euro.ucsc.edu/). b Schematic representation of human NFKBIA
(IκBα) gene showing the peaks for MNT binding in the K562 cell line, together with the amplicons analyzed below by ChIP-PCR. The conserved REL-
binding sites obtained in the ENCODE project using the TFBS Conserved (tfbsConsSites) track are marked in red rectangles. The E-boxes found in
NFKBIA are marked in blue (CACGCG at +907 bp and CACGTG at +1899 bp). c ChIP of MNT (upper panel) or REL (lower panel) in LoVo cells on NFKBIA
promoter. TXNIP and MNT −842 used as positive controls and a region upstream MNT promoter (MNT −4729), as a negative control for MNT ChIP.
The data are shown as the mean ± S.D., n= 3, **P < 0.05; ***P < 0.01. d Re-ChIP of MNT with REL (MNT→ REL) and REL with p50 (REL→ p50) in LoVo
cells. MNT and REL ChIPs were also re-immunoprecipitated with IgG as a negative control of the technique. The data are shown as the mean ± S.D.,
n ≥ 3, *P < 0.1. e Model of the MNT regulation of NF-κB signaling. Our results indicate that in a high MNT-levels condition, MNT would be possibly
regulating NF-κB signaling by retaining REL dimers in the cytoplasm and by forming a complex with REL in the nucleus that would repress the genes
that are normally activated by REL dimers. When we silence MNT, REL dimers are released and they translocate into the nucleus, with the consequent
increase in NF-κB target genes and the activation of the pathway.
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bind and repress IκBα at least in some cell types, opens a
new level of regulation of the NF-κB pathway, i.e., the
MNT–REL mediated repression of genes otherwise acti-
vated by REL.
MNT pro-survival role has been described in several
models, although the exact mechanism responsible for
that remains unknown9,40,41. Here we describe the unex-
pected discovery of an interaction between MNT and
REL, an NF-κB pathway component, which has a key role
in regulating cell homeostasis. It can be hypothesized that
MNT would impair REL function by retaining REL dimers
in the cytoplasm and also by repressing REL-target genes
(Fig. 6e). Thus, the previously described effects of MNT
on proliferation could be in part exerted through the
regulation of NF-κB activity. Indeed, we have shown that
REL depletion abrogates the antiproliferative effect of
MNT depletion in at least two cell lines. This suggests
that the pro-survival activity of MNT is mediated at least
in part through REL. Moreover, it has been described that
REL induces MYC expression42–45. Considering the
MYC-MNT antagonism, it would be possible that MNT
would control MYC levels through the inhibition of REL
functions. Furthermore, loss of MNT in T-cells leads to a
disruption of T-cell development and lymphomagen-
esis40,41. As REL is also important for Th1 cell differ-
entiation46, it is possible that the effects of MNT on the
immune system are related to its interaction with REL
In summary, our results show unprecedented evidence
of an MNT–REL interaction, which links the MYC-MNT
with the NF-kB pathways and opens a new path to the
understanding of MNT’s wide functions in cell biology.
Materials and methods
Cell culture, transfections, and lentiviral transduction
Cell lines were obtained from ATCC and grown in
either RPMI-1640 or DMEM (Corning) supplemented
with 10% fetal bovine serum (Gibco, ThermoFisher Sci-
entific, Waltham, MA, USA), 150 µg/mL of gentamicin,
and 2 µg/mL of ciprofloxacin. All cells tested negative for
Mycoplasma infection by PCR. UR61 derivate from PC12
cells47. URMax34 cell line derives from UR61 and
expresses a MAX gene inducible by ZnSO4 (100 µM
ZnSO4 for 24 h)
4, LoVo cells were transfected with
ScreenFect A reagent (Screenfect, Eggenstein-Leopold-
shafen, Germany), following the manufacture’s indica-
tions and using the reagent at 3× µg DNA. C6 were
transfected with polyethyleneimine reagent (PEI, Poly-
sciences, Warrington, PA, USA), using 2.5 µg of PEI per
µg of DNA. UR61 and URMax34 cells were transfected
using the Ingenio Electroporation solution (Mirus) in an
Amaxa nucleofector. Transfected plasmids were human
MNT (pCMVSport6-MNT, Origene Technologies,
Rockville, MD, USA); mouse WT MNT-HA, ΔbHLH
MNT-HA (murine MNT carrying a deletion of amino
acids 221–272), ΔCt1 MNT-HA (murine MNT carrying a
deletion of 276 amino acids in the C-terminal region and
tagged with HA), ΔNt1 MNT-HA (murine MNT carrying
a deletion of amino acids 1–300), and ΔNt2 MNT-HA
(murine MNT carrying a deletion of amino acids 1–271).
MNT deletion constructs were made from the pcDNA3.1
WT MNT-HA48. This plasmid contains the mouse MNT
sequence together with a hemagglutinin (HA) tag at its C-
terminal domain. By designing different primers we gen-
erated the fragments corresponding to ΔCt1, ΔNt1, and
ΔNt2 constructs, which were inserted into the BamHI
and EcoRI sites of the pcDNA3, carrying a zeocin resis-
tance gene and an HA tag.
As for REL plasmids, we used mouse c-Rel cFlag
pcDNA3 (gift from Stephen Smale, RRID:
Addgene_20013, http://n2t.net/addgene:20013); human
pcDNA-FLAG-REL (RRID:Addgene_27253, http://n2t.
net/addgene:27253)49 and human pcDNA-FLAG-
RELΔRID with a deletion of 323–422 amino acids
(Addgene # 27265; http://n2t.net/addgene:27265; RRID:
Addgene_27265)28 (both gifts from Thomas Gilmore).
Lentiviral production was performed as previously
described50, and polybrene at 3 µg/mL was used to
increase the infection efficiency. Lentiviral particles car-
ried a scrambled short-hairpin RNA as a control, shSCR
(SHC016-1EA) or two short-hairpin RNAs against MNT
human gene, shMNT (TCR0000234788 and
TRCN0000235815), shREL (human TRCN0000435698
and mouse TRCN0000042551) from Sigma-Aldrich, St.
Louis, MO, USA. Activation of the NF-κB’s pathway was
achieved by TNFα (Peprotech, Rocky Hill, CT, USA) sti-
mulation for 30 min at 25–100 ng/mL.
RNA extraction and expression analysis
For qPCR, total RNA was isolated using the TRI
Reagent® Solution (Invitrogen, ThermoFisher Scientific,
Waltham, MA, USA). The cDNA was generated by
reverse transcription (RT) using the iScript (Bio-Rad,
Hercules, CA, USA). Quantitative polymerase chain
reaction (qPCR) was performed with specific primers
(Supplementary Table 2) using the iTaq™ Universal
SYBR® Green Supermix (Bio-Rad) and CFX ConnectTM
Real-Time PCR Detection System (Bio-Rad). RNA was
converted into cDNA and analyzed as described51. Levels
of mRNA were normalized against RPS14 (ribosomal
protein S14) mRNA levels.
Immunoprecipitation assays and immunoblot
For the immunoprecipitation assays, lysates were
obtained using the 1% NP-40 IP lysis buffer (50 mM Tris-
HCl pH 7.5, 150mM NaCl, 1% NP-40, 1 mM EDTA pH 8,
0.5 mM EGTA pH 8, and protease and phosphatase
inhibitors). For MNT–REL co-IP in LoVo cells, the cells
were lysed instead with a mild hypotonic buffer (10 mM
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HEPES pH 7, 10 mM KCl, 0.25 mM EDTA pH 8,
0.125 mM EGTA pH 8, 0.5 mM spermidine, 0.1% NP-40,
1 mM DTT and phosphatase and protease inhibitors).
Total cell lysis, immunoblots, and immunoprecipitations
(IPs) were performed as described51. The antibodies are
shown in Supplementary Table 3.
Preparation of cytoplasmic and nuclear fractions
Cytoplasmic extracts were obtained by a 30min lysis
with a hypotonic buffer (10 mM HEPES pH 7, 10 mM
KCl, 0.25 mM EDTA pH 8, 0.125 mM EGTA pH 8,
0.5 mM spermidine, 0.1% NP-40, 1 mM DTT, and phos-
phatase and protease inhibitors). Nuclear extracts were
obtained after a 5 min centrifugation at 1500 rpm and
lysed with 1% NP-40 IP lysis buffer (50 mM Tris-HCl pH
7.5, 150mM NaCl, 1% NP-40, 1 mM EDTA pH 8, 0.5 mM
EGTA pH 8, and protease and phosphatase inhibitors).
Once the lysates were obtained, the immunoprecipitation
and immunoblots were performed as described51.
Proteomic studies
Protein immunoprecipitation was carried out as
described in the protein immunoprecipitation section
except for the elution, which was carried out according to
the “On-beads digestion” protocol52. Briefly, beads-
immunocomplexes were trypsinized, in order to digest
the baits and the interacting proteins. After trypsinization,
protein samples were purified and finally resuspended in
0.1% (v:v) trifluoroacetic acid buffer to be analyzed by
mass spectrometry on a Q-Exactive mass spectrometer
(ThermoFisher Scientific) connected to an Ultimate
Ultra3000 chromatography system (ThermoFisher Scien-
tific). Mass spectra were analyzed using the MaxQuant
Software package of two technical replicates and biolo-
gical triplicates of the experimental and control samples.
Raw data files were searched against a Rattus norvegicus
(Rat) database (Uniprot RAT), using a mass accuracy of 6
ppm and 0.01 false discovery rate (FDR) at both peptide
and protein level.
Immunofluorescence staining
Adherent cells grown on glass coverslips were fixed with
% paraformaldehyde in PBS for 15min at room tem-
perature. Fixed cells were washed with PBS and permea-
bilized and blocked with 1% Triton X-100, 3% BSA in PBS
for 30 min. Then, cells were treated with blocking buffer
(3% BSA; 0.1% Triton X-100 in PBS) for 20 min, washed
with PBS and 0.1% Triton X-100 in PBS, and incubated
overnight at 4 °C with the primary antibodies 1:200 dilu-
ted in blocking buffer. The slides were incubated for 1 h at
room temperature with the secondary antibody con-
jugated with FITC (Jackson Laboratories, Bar Harbor, ME,
USA). The samples were mounted with ProLong Gold
Antifade mountant (ThermoFisher Scientific, Waltham,
MA, USA). Confocal images were obtained with a Leica
TCS SP5 microscope and processed and quantified using
the ImageJ software (https://imagej.nih.gov/ij/download.
html). The antibodies used are described in Supplemen-
tary Table 3.
In situ proximity ligation assay
In situ proximity ligation assay (PLA) was performed
with Duolink in situ Red Starter kit Mouse/Rabbit (Sigma-
Aldrich, St. Louis, MO, USA) according to the manu-
facturer’s instructions. In situ PLA-positive signals were
quantified using the ImageJ software. Cell samples were
visualized using a Zeiss Axio Imager M1 upright fluor-
escence microscope. The primary antibodies used are
described in Supplementary Table 3.
Proliferation assays
LoVo or UR61 cells were transfected with the pLKO
vector containing the shRNA sequences against MNT
(mix of two shRNAs) or REL (human for LoVo and
mouse/rat for UR61). After 48 h, puromycin was added
(1 μg/mL for LoVo and 0.1 μg/mL for UR61), which was
refreshed every 2–3 days. After 7 days of selection, cells
were washed with 1× PBS, stained with a crystal violet
solution (1% acetic acid, 1% methanol, 1% crystal violet
dye), and scanned. Finally, they were dissolved in a 10%
acetic acid solution and their absorbance was measured at
620 nm.
Luciferase reporters and assays
Cells were transfected with a mix of DNA constructs
specific for each experiment. We used a Firefly sp. luci-
ferase reporter gene regulated by five putative NF-ĸB
regulatory elements, pNF-ĸB-Luc30 (Stratagene, La Jolla,
CA, a gift from Jose P Vaqué) and wild-type human IκBα
promoter construct, which has been previously descri-
bed53. The firefly luciferase gene reporter vector carrying
five NF-ĸB binding sites was described. As a control, we
used a vector without any specific transcription regulatory
sequence. The pRL-null Renilla plasmid (Promega,
Madison, WI, USA) was also transfected. Luciferase
reporter assays were carried out with the Dual-Luciferase
Reporter (DLR) System (Promega), following the manu-
facturer’s instructions. Luminescence from both luciferase
reactions was measured with the Glomax Multi-detection
System (Promega). Firefly luminescence values were
normalized against Renilla luminescence values.
Chromatin immunoprecipitation (ChIP and Re-ChIP) assays
Total cell extracts were first lysed with a hypotonic
buffer (described in the “Nuclear/cytoplasm fractionation”
section) for purifying the nuclear compartment. Then,
nuclear lysis and chromatin immunoprecipitation (ChIP)
were performed essentially as described54. For the Re-
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ChIP experiments, we carried out an intermediary step of
elution with elution buffer plus 10mM DTT, 1 h at 37 °C.
The resulting DNA was incubated with the second anti-
body. Immunoprecipitated DNA was purified with the
QIAquick PCR Purification Kit (Qiagen, Germantown,
MD, USA) and analyzed by qPCR. The SYDH ENCODE
project was used as a reference for primer designing on
the human NFKBIA gene (http://genome.ucsc.edu/
ENCODE). The primers and antibodies used are descri-
bed in Supplementary Tables 2 and 3, respectively.
Statistical analysis
Student’s two-tail t-test was used to evaluate the sig-
nificance of differences between control and experimental
groups. A P-value was noted as *P < 0.1, **P < 0.05, ***P <
0.01.
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